Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by:Roche Holdings, Inc.
GUARANTYRoche Holdings Inc • October 31st, 1995 • Delaware
MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • March 7th, 2019 • Roche Holdings Inc • Delaware
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300, Philadelphia, PA (“Spark”), and Roche Holdings Inc, a Delaware company having an address at 1 DNA Way, South San Francisco, CA 94080 (“Company”). For purposes of this Agreement, references to each of Spark and Company, and corresponding references to disclosing party and receiving party herein, shall include the respective subsidiaries and other entities controlled, directly or indirectly by Spark or Company, as the case may be; provided, however, with respect to Company, the foregoing provision shall exclude Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo, 103-8324 (“Chugai”) unless the Company opts for such inclusion of Chugai and their respective subsidiaries by giving written notice
Amendment NO.1 to Agreement and Plan of MergerAgreement and Plan of Merger • July 8th, 2019 • Roche Holdings Inc
This Amendment NO.1 to Agreement and Plan of Merger (this “Amendment”) is entered into as of July 5, 2019 by and among Roche Holdings, Inc., a Delaware corporation (“Parent”), 022019 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Spark Therapeutics, Inc., a Delaware corporation (the “Company” and, together with Parent and Merger Sub, the “Parties”).
Call/Put: CallRoche Holdings Inc • February 28th, 2002
EXHIBIT 10.13 swissfirst ------------------------------------------------------ -------------------------- swissfirst Bank AG Bellariastrasse 23 CH-8002 Zurich OTC Contract Note REF: SWFB036 ------------------------ ---- The following transaction was...Roche Holdings Inc • February 28th, 2002
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Call/Put: CallRoche Holdings Inc • February 28th, 2002
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • March 25th, 2021 • Roche Holdings Inc • Delaware
This Confidentiality Agreement (“Agreement”) is entered into as of February 19, 2020 (“Effective Date”) by and between Roche Holdings, Inc., a Delaware corporation having its principal address at 1 DNA Way, South San Francisco, CA 94080 (“Recipient”), and GenMark Diagnostics, Inc., a Delaware corporation having its principal place of business at 5964 La Place Court, Carlsbad, California 92008 (together with its wholly owned subsidiaries, “Discloser”). The parties wish to protect and preserve the confidential and/or proprietary nature of information and materials that may be disclosed or made available to each other in connection with certain discussions, negotiations or dealings between the parties relating to Discloser’s exploration of certain business development and/or strategic initiatives (the “Purpose”). For purposes of this Agreement, references to each of Recipient and Discloser herein shall include the respective subsidiaries, affiliates and other entities controlled, directly
Confidentiality Agreement IGNYTA, INC.Confidentiality Agreement • January 10th, 2018 • Roche Holdings Inc • California
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
EXHIBIT 10.14 swissfirst ------------------------------------------------------ -------------------------- swissfirst Bank AG Bellariastrasse 23 CH-8002 Zurich OTC Contract Note REF: SWFB039 ------------------------ ---- The following transaction was...Roche Holdings Inc • February 28th, 2002
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
CONFORMED COPY -------------- AMENDED AND RESTATED GOVERNANCE AGREEMENT Agreement dated as of October 25, 1995 between Roche Holdings, Inc., a Delaware corporation ("Roche"), and Genentech, Inc., a Delaware corporation (the "Company"). WHEREAS, Roche,...Governance Agreement • October 31st, 1995 • Roche Holdings Inc • Delaware
Call/Put: CallRoche Holdings Inc • February 28th, 2002
EXHIBIT 10.16 swissfirst ------------------------------------------------------ -------------------------- swissfirst Bank AG Bellariastrasse 23 CH-8002 Zurich OTC Contract Note ------------------------ The following transaction was broked and...Roche Holdings Inc • February 28th, 2002
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: swissfirst Bank AG. for account Nr. 3671_0 -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Call/Put: CallRoche Holdings Inc • February 28th, 2002
Payment Instructions: -------------------------------------------------------------------------------- To be transmitted by telefax to swissfirst Bank AG: Telefax Number +4441-1-204 81 81 Acknowledged by: Roche Holdings, Inc.
Call/Put: CallRoche Holdings Inc • February 28th, 2002
